Annals of Hematology

Papers
(The H4-Index of Annals of Hematology is 22. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)
ArticleCitations
A case of acute promyelocytic leukemia with pericardial effusion successfully managed with colchicine during ATO administration68
Concomitant multiple sclerosis and polycythemia vera successfully treated with glatiramer acetate51
Refractory hepatosplenic T-cell lymphoma was successfully treated with salvage allogeneic hematopoietic stem cell transplantation combined with enhanced myeloablative preconditioning49
Real-life use of mTOR inhibitor-based therapy in adults with autoimmune cytopenia highlights strong efficacy in relapsing/refractory multi-lineage autoimmune cytopenia48
Correction to: Hemophagocytic lymphohistiocytosis in HIV-associated lymphoproliferative disorders47
Efficacy and safety of olverembatinib as maintenance therapy after allogeneic hematopoietic cell transplantation in Philadelphia chromosome–positive acute lymphoblastic leukemia46
Prognostic impact of TET2 mutations in patients with acute myeloid leukemia: HM-SCREEN-Japan 01 and 02 study44
Causes of death and treatment-related mortality in newly diagnosed childhood acute lymphoblastic leukemia treatment with Chinese Children’s Cancer Group study ALL-201543
Sufficient vitamin D is favorable for children with persistent and chronic immune thrombocytopenia39
Impact of race and ethnicity on outcomes after autologous stem cell transplantation for patients with newly diagnosed multiple myeloma38
The presence of idiopathic thrombocytopenic purpura and incidence of acute non-ST elevation myocardial infarction36
Clonal evolution analysis of a rare acute promyelocytic leukemia patient transforming from essential thrombocythemia34
CAG (cytarabine, aclarubicin and granulocyte colony-stimulating factor) regimen for core binding factor acute myeloid leukaemia with measurable residual disease32
Risk factors and outcome of Stenotrophomonas maltophilia infection after allogeneic hematopoietic stem cell transplantation: JSTCT, Transplant Complications Working Group32
Detection of circulating tumor DNA in cerebrospinal fluid prior to diagnosis of spinal cord lymphoma by flow cytometric and cytologic analyses30
Effectiveness of prophylactic antiviral therapy in reducing HBV reactivation for HBsAg-positive recipients following allogeneic hematopoietic stem cell transplantation: a multi-institutional experienc29
Refractory pure red cell aplasia associated with T-cell large granular lymphocyte leukemia treated by ruxolitinib28
Outcome of patients with diffuse large B-cell lymphoma and testicular involvement – real world data25
Optimizing hemophagocytic lymphohistiocytosis screening in children: validation of the HLH-Screen score24
Activity of trametinib as maintenance therapy after allogeneic hematopoietic stem cell transplantation in patients with relapsed or refractory RAS pathway-mutated hematologic malignancies23
Radiotherapy alone with curative intent in a case of limited-stage extranodal NK/T-cell lymphoma nasal type: a case report and review of the literature22
Health-related quality of life with daratumumab, bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone alone in transplant-ineligible patients with newly diagnosed multipl22
0.083143949508667